Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 3-methoxy xanthone compound in preparation of medicament for preventing and treating hyperuricemia

A technology for hyperuricemia and compounds, which is applied in the directions of drug combinations, pharmaceutical formulations, urinary system diseases, etc., can solve the problems such as the application of mangiferin and its aglycones that have not been reported in the literature, and achieve significant effects and high safety. , the effect of broad application prospects

Inactive Publication Date: 2012-06-20
KPC PHARM INC
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After literature search, so far, there is no literature reporting the application of high mangiferin and its aglycone in hyperuricemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 3-methoxy xanthone compound in preparation of medicament for preventing and treating hyperuricemia
  • Application of 3-methoxy xanthone compound in preparation of medicament for preventing and treating hyperuricemia
  • Application of 3-methoxy xanthone compound in preparation of medicament for preventing and treating hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: Effect of high mangiferin and its aglycone on hyperuricemia in mice

[0024] Experimental animals: healthy male Kunming mice, weighing 20-24 g, provided by the Experimental Animal Center of Kunming Medical College [Experimental Animal Production License No. SCXK (2009-2012)]. Raising conditions: room temperature 22±2°C, relative humidity 60-70%.

[0025] Grouping, modeling and administration: 60 Kunming mice were randomly divided into 6 groups, 10 in each group, half male and half male: normal control group, hyperuricemia model group, high mangiferin group, high mangiferin aglycon group, allopurinol control group, probenecid control group. The mice in the normal control group were intraperitoneally injected with 0.5% CMC-Na solution, and the mice in the other groups were injected intraperitoneally with oxonic acid potassium salt 380 mg / kg. One hour later, the mice in the normal control group and the hyperuricemia model group were injected with 0.5% CMC intra...

Embodiment 2

[0029] Example 2: Effect of high mangiferin and its aglycone on gouty arthritis in rats induced by sodium urate crystals (MSU)

[0030] Experimental animals: healthy male SD rats, weighing 220-270 g, provided by the Experimental Animal Center of Kunming Medical College [Experimental Animal Production License No. SCXK (2009-2012)]. Raising conditions: room temperature 22±2°C, relative humidity 60-70%.

[0031] Grouping, modeling and administration: 50 male SD rats were randomly divided into 5 groups, 10 in each group, half male and half male: normal control group, model group, high mangiferin group (100mg / kg), high mangiferin group Aglycone group (100mg / kg), indomethacin control group (10mg / kg). One hour after the intraperitoneal injection, the rats in the normal control group were injected with 50 μl of sterile PBS into the right knee joint cavity, and the rats in the other groups were injected with 50 μl of sterile 2% MSU into the right knee joint cavity. One hour later, th...

Embodiment 3

[0036] Example 3: Toxicological safety experiment of high mangiferin and its aglycone

[0037] Healthy ICR mice were selected, fasted for 12 hours before administration, gavaged once at 9:00 am and 4:00 pm respectively, observed continuously for 14 days after administration, and animal poisoning and death were recorded. After 14 days of continuous observation, the animals were sacrificed and autopsied to examine the pathological changes of various organs, and determine the maximum tolerated dose of intragastric administration in mice. The experimental results are shown in Table 3.

[0038]Table 3 The maximum tolerated dose experiment of high mangiferin and its aglycone mice gavage administration

[0039]

[0040] The above experiments show that the maximum tolerated dose of high-mangiferin mice gavage administration is greater than 22g / kg, and the maximum tolerated dose of high-mangiferin mice gavage administration is greater than 18g / kg, and the toxicity of both is signifi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Maximum tolerated doseaaaaaaaaaa
Maximum tolerated doseaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia and in particular relates to application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia as well as gout and lithangiuria brought by the hyperuricemia, and a medicine application way. The high mangiferin and aglycon thereof provided by the invention can be used for obviously reducing the concentration of serum uric acid in an animal for experiment and have the serum uric acid inhibition effect similar to that of a xanthine oxidase inhibition medicament allopurinol; and simultaneously, the high mangiferin and aglycon thereof provided by the invention can be used for obviously improving the concentration of uric acid in urine and have the uric acid excretion promoting function similar to that of a uric acid excretion promoting medicament probenecid. The high mangiferin and aglycon thereof provided by the invention are efficient, low in toxicity and high in safety, thus the high mangiferin and aglycon thereof are wide in application prospect.

Description

technical field [0001] The invention belongs to the field of medicine application, and relates to the application of 3-methoxyxanthone compound in the preparation and prevention of hyperuricemia drugs, in particular to the application of homomangiferin and its aglycone in the preparation and prevention of hyperuricemia and its complications application in medicine. Background technique [0002] Uric acid is the final product of purine metabolism in the human body. Hyperuricemia is a metabolic disease caused by excessive production of uric acid in the body and / or decreased excretion of uric acid due to the disorder of purine metabolism in the human body. It is mainly manifested as excessive uric acid in the blood. When the uric acid concentration in human plasma is greater than 417 μmol / L, it is easy to crystallize and precipitate, and deposits in the distal limbs with low body temperature and tissues with high acidity, such as muscles that are often exercised, joint cavitie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P19/06A61P13/04
Inventor 周荣光杨兆祥普俊学
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com